Head and Neck Squamous Cell Carcinoma
Merus B.V. focuses on metastatic and recurrent head and neck squamous cell carcinoma, including PD-L1-expressing disease in the first-line setting and disease that has progressed after prior PD-1 and platinum-based therapy.
- Incurable metastatic/recurrent HNSCC
- PD-L1-positive first-line disease
- Post-PD-1 and platinum-treated disease
Research activity in this area centers on petosemtamab alone and in combination with pembrolizumab.
Non-Small Cell Lung Cancer
The sponsor also studies non-small cell lung cancer, with trials addressing advanced disease and combination approaches involving EGFR-targeted therapy and immunotherapy.
- Advanced NSCLC
- Combination treatment strategies
- Antitumor activity assessment
Clinical development in this field includes MCLA-129 and petosemtamab in combination regimens.
Colorectal Cancer
Merus B.V. includes metastatic colorectal cancer among its areas of interest, reflecting activity in advanced solid tumor oncology.
- Metastatic colorectal cancer
- Advanced solid tumors
- Antitumor response evaluation
These studies align with broader investigation of targeted antibody-based therapies in difficult-to-treat malignancies.
Solid Tumors
The company maintains research activity across malignant solid tumors and advanced solid tumor populations, including patients with incurable or metastatic disease.
- Malignant solid tumors
- Advanced and recurrent disease
- Single-agent and combination therapy development
Work in this area includes evaluation of objective response rate, progression-free survival, duration of response, and overall survival.
